TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12392873

Group type: EXPERIMENTAL
Intervention: 7.0 kcal/kg/week in 3 days/week
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 7.0 kcal/kg/week in 5 days/week
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 17.5 kcal/kg/week in 3 days/week
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 17.5 kcal/kg/week in 5 days/week
Number of subjects: 80

Group type: COMPARATOR
Intervention: 3 days/week of stretching and flexibility exercises for 15 to 20 min/session
Number of subjects: 80
Study: 10532980

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg orally twice daily
Number of subjects: 172

Group type: COMPARATOR
Intervention: Pivampicillin 700 mg orally twice daily
Number of subjects: 172
Study: 8640144

Group type: EXPERIMENTAL
Intervention: Catalet C
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Catalet D
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 2279257

Group type: EXPERIMENTAL
Intervention: 200 mg ibopamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: 40 mg furosemide
Number of subjects: 12

Group type: COMPARATOR
Intervention: 200 mg ibopamine + 40 mg furosemide
Number of subjects: 12
Study: 6775520

Group type: EXPERIMENTAL
Intervention: Reconstituted skimmed milk powder (SMP)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: SMP and sandwich
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: SMP and lactase
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Diluted (1:1) evaporated whole milk (EM)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: EM and sandwich
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: EM and lactase
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 104
Study: 30587088

Group type: EXPERIMENTAL
Intervention: Evidence-based strategies to enhance school environments
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-SGM-specific factors
Number of subjects: 42

Group type: COMPARATOR
Intervention: SGM-specific factors
Number of subjects: 42

Group type: COMPARATOR
Intervention: Facilitating factors
Number of subjects: 42
Study: 31503332

Group type: EXPERIMENTAL
Intervention: Trabectedin (1.5 mg/m2)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Dacarbazine (1 g/m2 over 20-120 minutes)
Number of subjects: 378
Study: 28988962

Group type: EXPERIMENTAL
Intervention: Prehospital cooling (surface ice packs, cold saline infusion, wristband reminders)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Control (usual resuscitation and transport)
Number of subjects: 585
Study: 25627449

Group type: EXPERIMENTAL
Intervention: Strongman training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 30
Study: 23871731

Group type: EXPERIMENTAL
Intervention: More rapid intravenous fluid treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Slower intravenous fluid treatment
Number of subjects: 19
Study: 21315515

Group type: EXPERIMENTAL
Intervention: Written disclosure
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Spoken disclosure
Number of subjects: 181

Group type: COMPARATOR
Intervention: Positive control group
Number of subjects: 181

Group type: COMPARATOR
Intervention: Neutral control group
Number of subjects: 181
Study: 19369667

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1442

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1442
Study: 11395616

Group type: EXPERIMENTAL
Intervention: Single-dilator technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Multiple-dilator technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 50
Study: 9360734

Group type: EXPERIMENTAL
Intervention: Fashion magazines
Number of subjects: 39

Group type: COMPARATOR
Intervention: News magazines
Number of subjects: 39
Study: 8484698

Group type: EXPERIMENTAL
Intervention: Adjuvant oestrogen treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3318402

Group type: EXPERIMENTAL
Intervention: 15(R)-15-methyl prostaglandin E2 (Arbacet) (10 micrograms, 0.5 h before each meal and at bedtime)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 28960914

Group type: EXPERIMENTAL
Intervention: CPAP (10 cmH2O)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: EPAP (10 cmH2O)
Number of subjects: 21

Group type: COMPARATOR
Intervention: CPAP and EPAP
Number of subjects: 21
Study: 27463067

Group type: EXPERIMENTAL
Intervention: SHIFT intervention (weight-loss competition with body weight and behavioral self-monitoring, computer-based training, and motivational interviewing)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Usual practice control
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: SHIFT intervention
Number of subjects: 452
Study: 24843959

Group type: EXPERIMENTAL
Intervention: Fire filiform needle combined with mild moxibustion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gabapentin combined with sham acupuncture
Number of subjects: 100
Study: 21464154

Group type: COMPARATOR
Intervention: Gemcitabine (1250 mg/m2 on days 1 and 8) and cisplatin (75 mg/m2 on day 1)
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1250 mg/m2 on days 1 and 8), cisplatin (75 mg/m2 on day 1), and PF-3512676 (0.2 mg/kg on days 8 and 15 of each chemotherapy cycle)
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: Gemcitabine and cisplatin with PF-3512676
Number of subjects: 839

Group type: COMPARATOR
Intervention: Gemcitabine and cisplatin
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: PF-3512676
Number of subjects: 839
Study: 20643245

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 999

Group type: COMPARATOR
Intervention: Simvastatin 20 to 40 mg/day
Number of subjects: 999
Study: 18210954

Group type: EXPERIMENTAL
Intervention: Topical telbermin (72 microg/cm2)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 16623815

Group type: EXPERIMENTAL
Intervention: Tacrolimus monotherapy (MT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Triple therapy (TT)
Number of subjects: 56
Study: 14674507

Group type: EXPERIMENTAL
Intervention: Pin-retained amalgam (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bonded amalgam (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Resin composite (Group C)
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-viscosity glass-ionomer (Group D)
Number of subjects: 40
Study: 10965637

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 145
Study: 8985850

Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate solution (45 mL/1.7 m2/dose)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Polyethylene glycol-based solution (4 L/1.7 m2)
Number of subjects: 34
Study: 1335979

Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 6525441

Group type: EXPERIMENTAL
Intervention: 20 mg of prednisone as a reference solution or as a tablet in a 6‐week, six‐way crossover design
Number of subjects: 18

Group type: COMPARATOR
Intervention: Dissolution tests on five commercial tablet forms
Number of subjects: 18
Study: 31551229

Group type: EXPERIMENTAL
Intervention: PICC catheter parenteral nutrition support
Number of subjects: 140

Group type: COMPARATOR
Intervention: Central venous catheter (CVC) nutrition support
Number of subjects: 140
Study: 29270612

Group type: EXPERIMENTAL
Intervention: Direct therapy for 8 to 12 weeks
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Indirect therapy for 8 to 12 weeks
Number of subjects: 114

Group type: COMPARATOR
Intervention: Direct therapy
Number of subjects: 114

Group type: COMPARATOR
Intervention: Both therapies
Number of subjects: 114
Study: 26818059

Group type: EXPERIMENTAL
Intervention: Titration PAP
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 6-week PAP therapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 17
Study: 25579524

Group type: EXPERIMENTAL
Intervention: Electron beam therapy (16 Gy in 8 fractions)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy (3DCRT) (16 Gy in 8 fractions)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both arms (Electron and 3DCRT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 3DCRT
Number of subjects: 50
Study: 22279526

Group type: EXPERIMENTAL
Intervention: Behavioral priming with experimenters believing participants would walk slower
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavioral priming with experimenters believing participants would walk faster
Number of subjects: 0
Study: 19207632

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF) training, 36 sessions
Number of subjects: 102

Group type: COMPARATOR
Intervention: Computerised attention skills training (control)
Number of subjects: 102
Study: 17015004

Group type: EXPERIMENTAL
Intervention: EBUS-D (distance measured from bronchial orifice to lesion); 57 patients
Number of subjects: 113

Group type: COMPARATOR
Intervention: EBUS (biopsy forceps advanced regardless of distance); 56 patients
Number of subjects: 113
Study: 14698542

Group type: COMPARATOR
Intervention: MVP regimen (Mitomycin-C 8 mg/m2 d1, Vinblastine 4 mg/m2 d 1-8, Cisplatin 100 mg/m2 d1)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: MVC regimen (Mitomycin-C 8 mg/m2 d1, Vinblastine 4 mg/m2 d 1-8, Carboplatin 300 mg/m2 d1)
Number of subjects: 153
Study: 11533519

Group type: EXPERIMENTAL
Intervention: Buflomedil (600 mg once daily) for 12 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 80
Study: 9829381

Group type: EXPERIMENTAL
Intervention: Radioimmunoguided surgery (RIGS) with Iodine‐125 labeled monoclonal antibodies (MoAbs) B72.3 anti‐TAG
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Radioimmunoguided surgery (RIGS) with FO23C5 anti‐carcinoembryonic antigen (CEA)
Number of subjects: 21
Study: 8035029

Group type: EXPERIMENTAL
Intervention: Paromomycin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2660872

Group type: EXPERIMENTAL
Intervention: Sultamicillin
Number of subjects: 426

Group type: COMPARATOR
Intervention: Bacampicillin
Number of subjects: 426
Study: 4929367

Group type: EXPERIMENTAL
Intervention: Azathioprine (2.5 mg/kg/day) and Prednisone (20 mg/day for adults, 0.5 mg/kg/day for children)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 149
Study: 31537557

Group type: COMPARATOR
Intervention: Standard service with a smartphone for outcome measurement only
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Standard service plus a smartphone including the motivational smartphone app
Number of subjects: 72
Study: 28114993

Group type: EXPERIMENTAL
Intervention: Telephone interview administration of the EuroQol Health Related Quality of Life survey
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patient-completed form administration of the EuroQol Health Related Quality of Life survey
Number of subjects: 90

Group type: COMPARATOR
Intervention: Both methods of administration (telephone and patient-completed)
Number of subjects: 90
Study: 26007221

Group type: EXPERIMENTAL
Intervention: SCC group (6 hours of didactic lectures and 8 hours of virtual reality simulation-based training with expert feedback)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: SCC group
Number of subjects: 33

Group type: COMPARATOR
Intervention: SRL group (self-regulated learning with 8 hours of simulator practice)
Number of subjects: 33
Study: 23225897

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment in infants (IPTi) with sulfadoxine‐pyrimethamine (SP) administered at 2, 3, and 9 months of age
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison areas without IPTi
Number of subjects: 0
Study: 20473880

Group type: EXPERIMENTAL
Intervention: Mixed-type liposarcoma cases (n=8)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (n=15)
Number of subjects: 8
Study: 19487704

Group type: EXPERIMENTAL
Intervention: Educational intervention to improve breastfeeding knowledge and attitudes
Number of subjects: 551

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 551
Study: 16919749

Group type: EXPERIMENTAL
Intervention: Injected diacetylmorphine (DAM) plus oral methadone (average DAM dosage: 274.5 mg/day; average methadone dosage: 42.6 mg/day) for 9 months
Number of subjects: 62

Group type: COMPARATOR
Intervention: Oral methadone (average dosage: 105 mg/day) for 9 months
Number of subjects: 62
Study: 15788738

Group type: EXPERIMENTAL
Intervention: Arginine supplementation (8.5 g for 4 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Isonitrogenous supplement (control)
Number of subjects: 26
Study: 11883986

Group type: EXPERIMENTAL
Intervention: Task switching with instructional cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task switching
Number of subjects: 0
Study: 10462426

Group type: EXPERIMENTAL
Intervention: Condom usage during sexual intercourse
Number of subjects: 0

Group type: COMPARATOR
Intervention: No condom usage during sexual intercourse
Number of subjects: 0
Study: 7790242

Group type: EXPERIMENTAL
Intervention: 67.2 Gy
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: 72.0 Gy
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: 76.8 Gy
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: 81.6 Gy
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Daily interfraction interval <= 4.5 h
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Daily interfraction interval > 4.5 h
Number of subjects: 399
Study: 2400374

Group type: EXPERIMENTAL
Intervention: Fixation on a central target
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Restricted visual field (15 degrees)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (entire visual field, no fixation)
Number of subjects: 45
Study: 410053

Group type: EXPERIMENTAL
Intervention: DA antagonist (droperidol)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ACh agonist (physostigmine)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Deanol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31206748

Group type: EXPERIMENTAL
Intervention: Randomised Controlled Trials (RCTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational Studies (OP)
Number of subjects: 0
Study: 28867267

Group type: EXPERIMENTAL
Intervention: One4All intervention
Number of subjects: 478

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 478
Study: 25156527

Group type: EXPERIMENTAL
Intervention: Family-centered secondhand smoke intervention involving 3 home visits in the first 3 months of the infants' lives (plus usual care)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 293
Study: 22532236

Group type: EXPERIMENTAL
Intervention: Higher amount of physical exercise
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: High motivation and retirement
Number of subjects: 1292
Study: 21944629

Group type: EXPERIMENTAL
Intervention: Major Hepatectomy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Other Procedures
Number of subjects: 95
Study: 19857081

Group type: EXPERIMENTAL
Intervention: Flavocoxid 250 mg twice a day
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 17280748

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine with QS21 adjuvant
Number of subjects: 30

Group type: COMPARATOR
Intervention: Inactivated influenza vaccine without QS21 adjuvant
Number of subjects: 30
Study: 14982478

Group type: EXPERIMENTAL
Intervention: Irradiation to the scalp for tinea capitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjusted dosimetry accounting for uncertainties
Number of subjects: 0
Study: 11557467

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir (10 mg/kg every 8 h for 14 days) followed by oral acyclovir (800 mg q6h for 42 days)
Number of subjects: 10
Study: 9782813

Group type: EXPERIMENTAL
Intervention: Futuro wrist orthosis
Number of subjects: 10

Group type: COMPARATOR
Intervention: ThermoLyn wrist orthosis
Number of subjects: 10
Study: 8147630

Group type: EXPERIMENTAL
Intervention: Nonwashed shed mediastinal blood (group 1; n = 16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Liquid preserved packed red blood cells (group 2; n = 16)
Number of subjects: 32
Study: 2842266

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) administered subcutaneously, 7,500 anti activated factor X Units once a day for 7 days
Number of subjects: 173

Group type: COMPARATOR
Intervention: Calcium heparin (CH) administered subcutaneously, 5,000 International Units t.i.d. for 7 days
Number of subjects: 173
Study: 31808656

Group type: COMPARATOR
Intervention: Intravenous opioid with 1 mg/kg tramadol HCl (Group O)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided quadratus lumborum block (Group B)
Number of subjects: 40
Study: 30747501

Group type: EXPERIMENTAL
Intervention: Etanercept monotherapy (50 mg subcutaneous weekly)
Number of subjects: 851

Group type: COMPARATOR
Intervention: Methotrexate monotherapy (20 mg oral weekly)
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Combination therapy (Etanercept 50 mg subcutaneous weekly + Methotrexate 20 mg oral weekly)
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Etanercept monotherapy and Combination therapy
Number of subjects: 851
Study: 28628970

Group type: EXPERIMENTAL
Intervention: Ankascin 568 (500 mg capsules, 2 capsules daily for 8 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25043476

Group type: EXPERIMENTAL
Intervention: High-risk HPV positivity during the first screening round
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: High-risk HPV positivity during the second screening round
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: High-risk HPV positivity during the third screening round
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: High-risk HPV positivity for >9 years of follow-up
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: HPV16/18/31/33
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: HPV35/45/52/58
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: HPV39/51/56/59/66/68
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: HPV16
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: HPV16/18/31/33/45/52/58
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: All high-risk HPV types
Number of subjects: 1000
Study: 23281147

Group type: EXPERIMENTAL
Intervention: BTX‐A dilution of 100 U in 1 ml of saline (Group A)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: BTX‐A dilution of 100 U in 2 ml of saline (Group B)
Number of subjects: 10
Study: 21474843

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 18972731

Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion
Number of subjects: 85

Group type: COMPARATOR
Intervention: Chinese drug
Number of subjects: 85
Study: 16242900

Group type: EXPERIMENTAL
Intervention: 4 weeks of clinical supervision
Number of subjects: 61

Group type: COMPARATOR
Intervention: No clinical supervision (control group)
Number of subjects: 61
Study: 12717239

Group type: EXPERIMENTAL
Intervention: eCsA (CsA elimination)
Number of subjects: 133

Group type: COMPARATOR
Intervention: mCsA (CsA dose minimization)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Both groups (eCsA and mCsA)
Number of subjects: 133
Study: 10856412

Group type: EXPERIMENTAL
Intervention: Chart abstraction
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standardized-patient checklist
Number of subjects: 20
Study: 9382004

Group type: EXPERIMENTAL
Intervention: Medial approach
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lateral approach
Number of subjects: 50
Study: 1608680

Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin
Number of subjects: 218

Group type: COMPARATOR
Intervention: Tobramycin and metronidazole
Number of subjects: 218
Study: 3985516

Group type: EXPERIMENTAL
Intervention: Continuing medical education (2-hour educational program)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Continuing medical education in multitopic and unitopic contexts
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Continuing medical education (all groups)
Number of subjects: 103
Study: 30406325

Group type: EXPERIMENTAL
Intervention: Quilting sutures (Group B)
Number of subjects: 370

Group type: COMPARATOR
Intervention: No quilting sutures (Group A)
Number of subjects: 370
Study: 28855183

Group type: EXPERIMENTAL
Intervention: Online tailored advice (TrailS6)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control group (no further intervention)
Number of subjects: 232
Study: 27611748

Group type: EXPERIMENTAL
Intervention: Positioning stent
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no positioning stent)
Number of subjects: 30
Study: 24383431

Group type: EXPERIMENTAL
Intervention: Healthy diet without cereal grains and dairy products
Number of subjects: 15
Study: 21482060

Group type: EXPERIMENTAL
Intervention: Pictorial warnings
Number of subjects: 88

Group type: COMPARATOR
Intervention: Written warnings
Number of subjects: 88
Study: 20093665

Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Combination of AIT and ST (COM)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study: 19368299

Group type: EXPERIMENTAL
Intervention: Quality protein maize (QPM)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional maize
Number of subjects: 48
Study: 16470490

Group type: EXPERIMENTAL
Intervention: Intravenous PD 123319 (10 mcg/minute for 5 minutes)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12419114

Group type: EXPERIMENTAL
Intervention: Home care (HC) offered at the moment of AIDS diagnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home care (HC) offered six months from diagnosis (Control Group)
Number of subjects: 0
Study: 11532889

Group type: EXPERIMENTAL
Intervention: Vocal responses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual responses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatial processing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal processing
Number of subjects: 0